Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

‘Mothballing’ Oxfordshire vaccine centre a mistake, former adviser says

The vaccine manufacturing and innovation centre was sold to US drugs firm Catelant in 2022.

Nilima Marshall
Wednesday 28 February 2024 11:29 EST
The £200 million vaccine manufacturing and innovation centre was set up in 2017 (Andrew Matthews/PA)
The £200 million vaccine manufacturing and innovation centre was set up in 2017 (Andrew Matthews/PA) (PA Archive)

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

The “mothballing” of a government-funded vaccine manufacturing centre that was sold to a private pharmaceutical company has been described as a “mistake”.

The £200 million vaccine manufacturing and innovation centre (VMIC) was set up in 2017 in Harwell, Oxfordshire, as a not-for-profit company with the aim of combining vaccine research and manufacturing in one place.

It was sold to US-based Catelant in 2022 before its construction was finished, with campaigners raising concerns about the sale to a profit-making business.

Catelant later announced it was delaying the project, leading to renewed fears about the UK’s future vaccine-manufacturing capabilities.

Ian McCubbin, former industry adviser at the UK’s vaccine taskforce, told MPs at the Science, Innovation and Technology Committee: “I think (mothballing) it probably was a mistake, but the reason I think it was sold was the facility had got bigger.

“It was very, very expensive to run.

“What do you do with a facility that’s expensive to run but you’re actually not doing anything (for) a pandemic?”

He added: “If that facility was in place, not only physically we’d be able to do more work, but it would have a nucleus around which other expertise could gather and I could not overestimate how important that is in a community to make things work.

“So, from a straightforward pandemic preparedness point of view, that is a mistake.”

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in